‹ ›
MYP_085774
← PREVIOUS NEXT → BACK
Basic Information
LP-86
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
not Standard
29 amino acids
-
contains X representing unresolved or non-standard residue
Sequence
LEANIEELLKKAEEQQKKNEEELKKLEKX
Physicochemical Analysis
0.00 Da
0.00
0.00
0.00
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0333211 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
C16 = palmitic acid at 29; C16 = palmitic acid
Bio-Activity Profile
Antiviral
HIV-1 89.6 subtype B
56
IC50
PMID29899103 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29899103/
RECORD: Rec_0337772 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 29 is Cys-Chol(cholesterol)
Bio-Activity Profile
Antiviral Anti-SIV Fusion inhibition
SIV (239,PBJ) | TZM-bl cells
0.000005-0.000006 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperDesign and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. | Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y. | J Virol. 2019 May 15;93(11):e02312-18. | DOI:10.1128/JVI.02312-18 | PMID:30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
RECORD: Rec_0347322 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
C16 = palmitic acid at 29; C16 = palmitic acid
Bio-Activity Profile
Antiviral
SIV 239
0.00004 μM
IC50
PMID29899103 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29899103/
RECORD: Rec_0350817 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 29 is Cys-Chol(cholesterol)
Bio-Activity Profile
Antimicrobial Antiviral
SIV(239,PBJ):inhibition of virus infection in TZM-bl cells
0.000005-0.000006 μM
IC50
PaperPubMed PMID: 30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
RECORD: Rec_0352517 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 29 is Cys-Chol(cholesterol)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 NL4-3 (X4) | TZM-bl cells
0.00000043±0.00000003 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperDesign and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. | Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y. | J Virol. 2019 May 15;93(11):e02312-18. | DOI:10.1128/JVI.02312-18 | PMID:30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
FIRST PREV 1 ... 3 4 5 6 7 NEXT LAST
Showing 5 records on this page · Page 5 of 7